U46619

From Wikipedia, the free encyclopedia
  (Redirected from U-46619)
Jump to navigation Jump to search
U46619
U46619.png
Names
IUPAC name
(Z)-7-[(1S,4R,5R,6S)-5-[(E,3S)-3-hydroxyoct-1-enyl]-3-oxabicyclo[2.2.1]heptan-6-yl]hept-5-enoic acid
Identifiers
3D model (JSmol)
ChEMBL
ECHA InfoCard 100.164.944
Properties
C21H34O4
Molar mass 350.49 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is ☑Y☒N ?)
Infobox references

U46619 is a stable synthetic analog of the endoperoxide prostaglandin PGH2 first prepared in 1975,[1] and acts as a thromboxane A2 (TP) receptor agonist.[2] It potently stimulates TP receptor-mediated, but not other prostaglandin receptor-mediated responses in various in vitro preparations.[3] and exhibits many properties similar to thromboxane A2, including shape change and aggregation of platelets [4] and smooth muscle contraction. U46619 is a vasoconstrictor that mimics the hydroosmotic effect of vasopressin.[5]

References[edit]

  1. ^ Bundy, G. L. (1975). "Synthesis of prostaglandin endoperoxide analogs". Tetrahedron Letters. 24 (24): 1957–1960. doi:10.1016/S0040-4039(00)72333-1.
  2. ^ "U 46619". www.tocris.com. Missing or empty |url= (help)
  3. ^ "U 46619". www.tocris.com. Missing or empty |url= (help)
  4. ^ Liel, N.; Mais, D.E.; Halushka, P.V (1987). "Binding of a thromboxane A2/prostaglandin H2 agonist [3H]U46619 to washed human platelets". Prostaglandins. 33: 789–797. doi:10.1016/0090-6980(87)90107-9.
  5. ^ Burch, Ronald M.; Halushka, Perry V. (1983). "Calcium-45 fluxes in isolated toad bladder epithelial cells: effects of agents which alter water or sodium transport". Journal of Pharmacology and Experimental Therapeutics. 224 (1): 108–17. PMID 6294273.